Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas | Blood Advances | American Society of Hematology

Polatuzumab successfully bridged 51% of patients to CAR-T in this retrospective study with a 6 months OS of 77.9%.

Read the full article here

Related Articles